Silence Therapeutics PLC Silence Appoints Senior VP of BD, AM and NPD. (2906K)
01 9월 2021 - 3:00PM
UK Regulatory
TIDMSLN
RNS Number : 2906K
Silence Therapeutics PLC
01 September 2021
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice
President, Business Development, Alliance Management and New
Product Development
1 September 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced the appointment of
John Strafford, Ph.D., to the newly created role of Senior Vice
President, Business Development, Alliance Management and New
Product Development, effective immediately. John joined Silence in
2018 and has served as Vice President, Head of Business Development
and member of the Executive Leadership Team since 2019. In his new
role, John will continue to drive all business development and
alliance management activities as well as lead the new product
development function, helping to define the future commercial
strategy for the Company's proprietary mRNAi GOLD(TM) development
pipeline.
Mark Rothera, President and Chief Executive Officer of Silence
Therapeutics, said: "John has played a critical role in
establishing key strategic partnerships that further expand our
portfolio of mRNAi GOLD(TM) platform programs and continues to
serve as an important source of non-dilutive capital. As we build
and advance our proprietary and partnered pipelines, John will be
taking on increasing responsibilities in this new role which
recognizes not only his prior efforts but my anticipation of all
the important work he will be doing during this transformative
period at Silence."
John has 14 years of business development and strategic
consulting experience in the biopharma industry. During his time at
Silence, John has led the formation of collaborations with
AstraZeneca, Mallinckrodt and Takeda as well as a range of
undisclosed research collaborations in support of our extra-hepatic
delivery strategy. Together, these collaborations have delivered
over $100 million in upfront payments and represent a total
potential deal value of over $6 billion. Before joining Silence,
John held positions of increasing responsibility at Antisoma,
Easton Associates, Novasecta and Concordia International.
John holds a PhD in Biochemical Engineering from University
College London, an MRes in Bioinformatics from the University of
York and a BSc in Molecular Biology from the University of
Edinburgh. In 2009 John was awarded the Pharma Licensing Group
(PLG) Business Development Best Newcomer of the Year Award.
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Investec Bank plc (Nominated Adviser and Tel: +44 (0) 20
Broker) 7597 5970
Daniel Adams/Gary Clarence
European PR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD(TM) platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
iron-loading anemia conditions. Silence also maintains ongoing
research and development collaborations with AstraZeneca,
Mallinckrodt Pharmaceuticals, and Takeda, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company's clinical and commercial prospects and
the anticipated timing of data reports from the Company's clinical
trials. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements,
including those risks identified in the Company's most recent
Admission Document and its amended Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on April 29, 2021.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCQFLFXFVLZBBX
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Silence Therapeutics (LSE:SLN)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
